Company Analysis
Sign in

Werewolf Therapeutics, Inc. (HOWL)

Nasdaq: HOWL · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.6
◀ Past 4.7● Present 3.7▶ Future 5.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Werewolf Therapeutics, Inc.’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 3 in 2024 and 1 in 2023
Applications published
24
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology6
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Werewolf Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
24 published
Werewolf Therapeutics, Inc. its own name
US, as the owner printed on each patent
10 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 15, 202512,275,769Activatable interleukin 12 polypeptides and methods of use thereofBiotechnologyWerewolf Therapeutics, Inc.
Sep 3, 202412,076,371Activatable cytokine polypeptides and methods of use thereofPharmaceuticalsWerewolf Therapeutics, Inc.
Jul 16, 202412,036,266Activatable cytokine polypeptides and methods of use thereofPharmaceuticalsWerewolf Therapeutics, Inc.
May 14, 202411,981,716Activatable interleukin-2 polypeptides and methods of use thereofBiotechnologyWerewolf Therapeutics, Inc.
Aug 29, 202311,739,132Separation moieties and methods of use thereofBiotechnologyWerewolf Therapeutics, Inc.
Dec 27, 202211,535,658Activatable interleukin-2 polypeptides and methods of use thereofBiotechnologyWerewolf Therapeutics, Inc.
Sep 27, 202211,453,710Activatable interleukin 12 polypeptides and methods of use thereofBiotechnologyWerewolf Therapeutics, Inc.
Jun 7, 202211,352,403Activatable interleukin-2 polypeptides and methods of use thereofBiotechnologyWerewolf Therapeutics, Inc.
Jun 30, 202010,696,724Activatable interleukin-2 polypeptidesBiotechnologyWerewolf Therapeutics, Inc.
Jun 30, 202010,696,723Activatable interleukin 12 polypeptidesBiotechnologyWerewolf Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 5, 20252025/0179138ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOFBiotechnologyWerewolf Therapeutics, Inc.
Nov 14, 20242024/0374687IL-2 PRODRUGPharmaceuticalsWerewolf Therapeutics, Inc.
Oct 31, 20242024/0358796ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOFPharmaceuticalsWerewolf Therapeutics, Inc.
Aug 8, 20242024/0262880ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOFBiotechnologyWerewolf Therapeutics, Inc.
Jul 4, 20242024/0216505INDUCIBLE CYTOKINE PRODRUG AND PD-1/PD-L1 COMBINATION THERAPYPharmaceuticalsWerewolf Therapeutics, Inc.
Jul 4, 20242024/0216474ACTIVATABLE INTERFERON POLYPEPTIDES AND METHODS OF USE THEREOFPharmaceuticalsWerewolf Therapeutics, Inc.
Jul 4, 20242024/0216470INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPYPharmaceuticalsWerewolf Therapeutics, Inc.
May 30, 20242024/0174725ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOFBiotechnologyWerewolf Therapeutics, Inc.
Feb 8, 20242024/0043488ACTIVATABLE IL-12 POLYPEPTIDES AND METHODS OF USE THEREOFPharmaceuticalsWerewolf Therapeutics, Inc.
Feb 1, 20242024/0033326Activatable Cytokine Polypeptides and Methods of Use ThereofPharmaceuticalsWerewolf Therapeutics, Inc. · patent 12,076,371 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Biotechnology 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton HOWL · research, not advice